ADVANCED SOLID TUMORS

This study tests a combination of two drugs, durvalumab and monalizumab, in adults with advanced solid tumors that have spread or come back. The goal is to see if the combination is safe and can shrink tumors. About 383 participants will receive the drugs, and researchers will mo…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests the safety of a new drug, PRL3-ZUMAB, in people with advanced solid tumors or blood cancers that have not responded to standard treatments. It is the first time this drug is given to humans, after showing good safety in animals. The main goal is to find the safes…

This early-phase study tests a new drug called SKB410 in about 54 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any early signs that the drug can control tumor growth. Participants receive mu…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests a drug called sotorasib, alone or with other cancer treatments, in adults with advanced solid tumors that have a specific KRAS G12C mutation. The main goals are to check safety and how well the drug works at shrinking or controlling tumors. About 610 participants…

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow cancer growth. About 112 participants …

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This study tests the drug pembrolizumab in about 1,600 people with various advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink or control the tumors. Participants receive pembrolizumab and are monitored for tumor respons…

This study tests a combination of two drugs, sacituzumab govitecan and berzosertib, in adults with small cell lung cancer or cancers that have stopped responding to PARP inhibitors. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive the d…

This early-stage study tests an experimental pill, ATV-1601, for people with advanced solid tumors or certain breast cancers that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 134 ad…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy can help shrink or control advanced solid tumors that are not responding well to treatment alone. About 57 adults with various advanced cancers will receive NP137 alongside their usual PD-…

This early-stage study tests an experimental drug called ABBV-706, alone or with other treatments, in adults with advanced solid tumors like small cell lung cancer and brain tumors. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 288 pa…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This early-phase study tests a new drug called HRS-6209 in 56 people with advanced solid tumors who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. This is a first step to see if the d…

This early-stage study tests a new drug, BAY 2965501, that activates T-cells to fight cancer. It is for people with advanced solid tumors (like skin, kidney, stomach, or lung cancer) that have not responded to other treatments. The study will test the drug alone or combined with …

This early-phase study tests a new drug called QTX3544, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change (KRAS G12V). The main goals are to check safety and find the right dose. About 237 adults with tumors that have…

This early-stage study tests a new drug, BAY 3375968, that targets a protein on immune-suppressing cells to help the body fight advanced solid tumors. About 129 adults with cancers like lung, breast, or melanoma that haven't responded to standard treatments will receive the drug …

This study is for people with advanced solid tumors who are already benefiting from the cancer drug spartalizumab in another Novartis study. It allows them to keep receiving the treatment while doctors closely monitor its long-term safety and side effects. About 120 participants …

This early-phase study tests a new drug, BMS-986484, alone or with another drug (nivolumab) in people with advanced solid tumors like lung, colorectal, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 adults with tumo…

This early-phase study tests a new drug called AMG 355, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumo…

This early-phase study tests an experimental drug called ZN-A-1041, given alone or with other cancer medicines, in people with HER2-positive advanced solid tumors (including breast cancer that has spread to the brain). The main goals are to check safety, find the right dose, and …

This early-phase study tests a new form of the chemotherapy drug topotecan, wrapped in liposomes, in about 96 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and understand side effects. The study inc…

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-stage study tests two experimental mRNA treatments (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors that have not responded to standard therapy. The goal is to check safety and tolerability, with mRNA-4200 given alongside a checkpoint inhibitor. This i…

This early-stage study tests a new treatment called hV01, a modified virus designed to infect and kill cancer cells while boosting the immune system. It involves 24 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check the safe…

This study is for adults with advanced solid tumors (like head and neck, breast, ovarian, or skin cancer) that haven't responded to standard treatments. Researchers want to understand how the drug pembrolizumab changes genes and immune markers in the blood and tumors. The goal is…